- Home
- IBRX vs CLM Comparison
IBRX vs CLM Comparison
Compare IBRX & CLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- CLM
- Stock Information
- Founded
- IBRX 2014
- CLM 1987
- Country
- IBRX United States
- CLM United States
- Employees
- IBRX N/A
- CLM N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- CLM Finance/Investors Services
- Sector
- IBRX Health Care
- CLM Finance
- Exchange
- IBRX Nasdaq
- CLM Nasdaq
- Market Cap
- IBRX 2.3B
- CLM 2.3B
- IPO Year
- IBRX N/A
- CLM N/A
- Fundamental
- Price
- IBRX $2.58
- CLM $8.28
- Analyst Decision
- IBRX Strong Buy
- CLM
- Analyst Count
- IBRX 6
- CLM 0
- Target Price
- IBRX $9.83
- CLM N/A
- AVG Volume (30 Days)
- IBRX 9.7M
- CLM 1.4M
- Earning Date
- IBRX 11-10-2025
- CLM 01-01-0001
- Dividend Yield
- IBRX N/A
- CLM 18.74%
- EPS Growth
- IBRX N/A
- CLM N/A
- EPS
- IBRX N/A
- CLM N/A
- Revenue
- IBRX $56,600,000.00
- CLM N/A
- Revenue This Year
- IBRX $629.94
- CLM N/A
- Revenue Next Year
- IBRX $109.91
- CLM N/A
- P/E Ratio
- IBRX N/A
- CLM N/A
- Revenue Growth
- IBRX 4227.22
- CLM N/A
- 52 Week Low
- IBRX $1.83
- CLM $6.25
- 52 Week High
- IBRX $6.82
- CLM $8.84
- Technical
- Relative Strength Index (RSI)
- IBRX 54.54
- CLM 52.40
- Support Level
- IBRX $2.30
- CLM $8.07
- Resistance Level
- IBRX $2.67
- CLM $8.27
- Average True Range (ATR)
- IBRX 0.12
- CLM 0.10
- MACD
- IBRX 0.01
- CLM -0.01
- Stochastic Oscillator
- IBRX 75.68
- CLM 46.67
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About CLM Cornerstone Strategic Value Fund Inc. New
Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, industrials, utilities, energy, telecommunication services, materials, and other sectors.